Skip to main
KLRS

Allovir Inc (KLRS) Stock Forecast & Price Target

Allovir Inc (KLRS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kalaris Therapeutics is positioned for success with its lead candidate TH103 which has already demonstrated promising preliminary data with significant improvements in BCVA and CST and a high level of patients remaining rescue-free for up to six months. Additionally, with the completion of enhancements to its manufacturing process and a strong management team, the company has addressed potential safety concerns and is well-positioned for success in the crowded market for wet AMD therapeutics.

Bears say

Kalaris Therapeutics is heavily reliant on the success of a single asset, TH103, which is currently in Phase 1b/2 clinical trials and may face challenges in effectively commercializing its products. There is also significant risk from market competition and potential delay in clinical development, regulatory approvals, or commercialization timelines. Additionally, the company has incurred significant losses and will require substantial funds to finance its pipeline, making its stock price vulnerable to market fluctuations and overall economic conditions.

Allovir Inc (KLRS) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allovir Inc (KLRS) Forecast

Analysts have given Allovir Inc (KLRS) a Buy based on their latest research and market trends.

According to 5 analysts, Allovir Inc (KLRS) has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allovir Inc (KLRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.